CO5700152A1 - Nuevos anticuerpos anti-igf-ir y sus usos - Google Patents

Nuevos anticuerpos anti-igf-ir y sus usos

Info

Publication number
CO5700152A1
CO5700152A1 CO05074351A CO05074351A CO5700152A1 CO 5700152 A1 CO5700152 A1 CO 5700152A1 CO 05074351 A CO05074351 A CO 05074351A CO 05074351 A CO05074351 A CO 05074351A CO 5700152 A1 CO5700152 A1 CO 5700152A1
Authority
CO
Colombia
Prior art keywords
sequence
cdr
igf
seq
identity
Prior art date
Application number
CO05074351A
Other languages
English (en)
Inventor
Liliana Goetsch
Original Assignee
Fabre Pierre Dermo Cosmetique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34950307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5700152(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fabre Pierre Dermo Cosmetique filed Critical Fabre Pierre Dermo Cosmetique
Publication of CO5700152A1 publication Critical patent/CO5700152A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

Un anticuerpo aislado, o uno de sus fragmentos funcionales, siendo dicho anticuerpo o uno de dichos fragmentos capaz de unirse al receptor del factor de crecimiento humano similar a insulina I IGF-IR y, si fuera necesario, de inhibir la unión natural de sus ligandos IGFI y/o IGF2, y/o capaz de inhibir específicamenfe la actividad tirosin-quinasa de dicho IGF-IR; caracterizado porque comprende una cadena liviana que comprende al menos una región determinante de complementariedad CDR elegida entre las CDRs de secuencia SEQ ID No. 1, 2 o 3, o al menos una CDR cuya secuencia tenga al menos un 80% de identidad después de una alineación óptima con la secuencia SEQ ID No. 1, 2 o 3 o porque comprende una cadena pesada que comprende al menos una CDR elegida entre las CDRs de secuencia SEQ ID Nos. 4, 5 y 6, o al menos una CDR cuya secuencia tenga al menos un 80% de identidad después de una alineación óptima con la secuencia SEQ ID No. 4, 5 y 6.
CO05074351A 2004-07-29 2005-07-28 Nuevos anticuerpos anti-igf-ir y sus usos CO5700152A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59193204P 2004-07-29 2004-07-29
FR0408379A FR2873699B1 (fr) 2004-07-29 2004-07-29 Nouveaux anticorps anti igf ir rt leurs utilisations

Publications (1)

Publication Number Publication Date
CO5700152A1 true CO5700152A1 (es) 2006-11-30

Family

ID=34950307

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05074351A CO5700152A1 (es) 2004-07-29 2005-07-28 Nuevos anticuerpos anti-igf-ir y sus usos

Country Status (23)

Country Link
US (3) US7854930B2 (es)
EP (4) EP2365006A3 (es)
JP (3) JP5016487B2 (es)
KR (1) KR101220635B1 (es)
CN (2) CN103951752A (es)
AR (1) AR050036A1 (es)
AU (1) AU2005268505B2 (es)
BR (1) BRPI0513890A (es)
CA (1) CA2575348A1 (es)
CO (1) CO5700152A1 (es)
FR (1) FR2873699B1 (es)
GT (1) GT200500205A (es)
HK (1) HK1102600A1 (es)
IL (2) IL181025A (es)
MX (1) MX2007001109A (es)
NO (1) NO20071093L (es)
NZ (2) NZ569718A (es)
PA (1) PA8640601A1 (es)
RU (2) RU2406729C2 (es)
SV (1) SV2006002182A (es)
TW (1) TWI432451B (es)
WO (1) WO2006013472A2 (es)
ZA (1) ZA200700593B (es)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
ATE514783T1 (de) 2003-11-12 2011-07-15 Schering Corp Plasmidsystem zur expression mehrerer gene
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
EP2283831A3 (en) 2004-12-03 2013-10-23 Merck Sharp & Dohme Corp. Biomakers for pre-selection of patients for anti-IGF1R therapy
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
PT2100618E (pt) 2005-06-17 2014-04-07 Philadelphia Health & Educatio Um anticorpo anti-pdgfr-alfa para o tratamento de cancro ósseo metastático
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
AP2008004569A0 (en) 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
KR20090114449A (ko) * 2007-02-14 2009-11-03 글락소 그룹 리미티드 Igf-ⅰr에 대한 항체
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
WO2009043049A2 (en) 2007-09-27 2009-04-02 Amgen Inc. Pharmaceutical formulations
EP2219602A1 (en) 2007-11-15 2010-08-25 Amgen, Inc Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
JP5458020B2 (ja) 2007-12-21 2014-04-02 ロシュ グリクアート アクチェンゲゼルシャフト 抗体の安定性試験
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
KR101436219B1 (ko) 2009-10-26 2014-09-01 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
US8444982B2 (en) * 2009-12-04 2013-05-21 The University Of Hong Kong Anti-IGF-IR antibodies and uses thereof
US20110200595A1 (en) 2010-02-18 2011-08-18 Roche Glycart TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
WO2011156373A1 (en) 2010-06-07 2011-12-15 Amgen Inc. Drug delivery device
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
HUE035281T2 (en) 2011-01-14 2018-05-02 Univ California Therapeutic antibodies to ROR-1 protein and methods of their use
AU2012212075A1 (en) 2011-02-02 2013-07-18 Amgen Inc. Methods and compositons relating to inhibition of IGF-1R
MX341790B (es) 2011-03-31 2016-09-02 Amgen Inc Adaptador de viales y sistema.
PT2699293T (pt) 2011-04-20 2019-05-21 Amgen Inc Aparelho de autoinjeção
IL308846A (en) 2011-10-14 2024-01-01 Amgen Inc Syringe and assembly method
US9700619B2 (en) 2011-11-11 2017-07-11 Duke University Combination drug therapy for the treatment of solid tumors
EP2631653A1 (en) 2012-02-24 2013-08-28 Charité - Universitätsmedizin Berlin Identification of modulators of binding properties of antibodies reactive with a member of the insulin receptor family
US10519245B2 (en) 2012-06-21 2019-12-31 Sorrento Therapeutics Inc. Antibodies which bind insulin-like growth factor receptor-1 (IGF1R) and methods of use thereof to treat cancer
US8980259B2 (en) 2012-07-20 2015-03-17 Novartis Ag Combination therapy
CN102830223A (zh) * 2012-08-14 2012-12-19 四川汇宇制药有限公司 一种筛选治疗哺乳动物肿瘤疾病药物的方法
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
AU2013348071B2 (en) 2012-11-21 2018-05-24 Amgen Inc. Drug delivery device
WO2014144096A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
TWI580452B (zh) 2013-03-15 2017-05-01 安美基公司 用於注射器之匣盒、注射器及使用包括自動注射器及匣盒之設備之方法
ES2853748T3 (es) 2013-03-22 2021-09-17 Amgen Inc Inyector y método de montaje
US9657059B2 (en) 2013-09-09 2017-05-23 Canimguide Therapeutics Ab Immune system modulators
ES2744837T3 (es) 2013-10-24 2020-02-26 Amgen Inc Inyector y procedimiento de ensamblaje
AU2014340174B2 (en) 2013-10-24 2019-09-12 Amgen Inc. Drug delivery system with temperature-sensitive control
WO2015119906A1 (en) 2014-02-05 2015-08-13 Amgen Inc. Drug delivery system with electromagnetic field generator
NZ725423A (en) * 2014-04-25 2023-07-28 Pf Medicament Igf-1r antibody and its use as addressing vehicle for the treatment of cancer
KR102496507B1 (ko) 2014-05-07 2023-02-03 암겐 인코포레이티드 충격 감소 요소들을 가진 자동 주사기
IL297356A (en) 2014-06-03 2022-12-01 Amgen Inc Controllable drug delivery system and method of use
CA2957960C (en) 2014-10-14 2023-08-22 Amgen, Inc. Drug injection device with visual and audible indicators
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
US10799630B2 (en) 2014-12-19 2020-10-13 Amgen Inc. Drug delivery device with proximity sensor
CA2976935C (en) 2015-02-17 2020-03-10 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3981450A1 (en) 2015-02-27 2022-04-13 Amgen, Inc Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2016144650A1 (en) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Immune system modulators and compositions
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
CN109195993B (zh) 2016-02-06 2022-05-10 岸迈生物科技有限公司 串联fab免疫球蛋白及其用途
ES2814287T3 (es) 2016-03-15 2021-03-26 Amgen Inc Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
CA3018426A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
WO2017200989A1 (en) 2016-05-16 2017-11-23 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
US20200261643A1 (en) 2016-10-25 2020-08-20 Amgen Inc. On-body injector
WO2018136398A1 (en) 2017-01-17 2018-07-26 Amgen Inc. Injection devices and related methods of use and assembly
AU2018221351B2 (en) 2017-02-17 2023-02-23 Amgen Inc. Insertion mechanism for drug delivery device
WO2018151890A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Drug delivery device with sterile fluid flowpath and related method of assembly
CA3050927A1 (en) 2017-03-06 2018-09-13 Brian Stonecipher Drug delivery device with activation prevention feature
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
IL268386B2 (en) 2017-03-09 2023-11-01 Amgen Inc Insertion mechanism for a drug delivery device
FI3600491T3 (fi) 2017-03-28 2023-10-20 Amgen Inc Männänvarren ja ruiskukokoonpanon järjestelmä ja menetelmä
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
MX2019015472A (es) 2017-06-22 2020-02-19 Amgen Inc Reduccion del impacto/choque de la activacion del mecanismo.
MA49461A (fr) 2017-06-23 2020-04-29 Amgen Inc Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
JP2020527376A (ja) 2017-07-21 2020-09-10 アムジエン・インコーポレーテツド 薬物容器のためのガス透過性シーリング部材及び組立方法
EP3658203B1 (en) 2017-07-25 2022-08-31 Amgen Inc. Drug delivery device with gear module and related method of assembly
MA49676A (fr) 2017-07-25 2020-06-03 Amgen Inc Dispositif d'administration de médicament doté d'un système d'accès à un récipient et procédé d'assemblage associé
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
EP3668567A1 (en) 2017-08-18 2020-06-24 Amgen Inc. Wearable injector with sterile adhesive patch
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
EP3691717B1 (en) 2017-10-04 2023-02-08 Amgen Inc. Flow adapter for drug delivery device
WO2019070552A1 (en) 2017-10-06 2019-04-11 Amgen Inc. DRUG DELIVERY DEVICE COMPRISING A LOCKOUT ASSEMBLY AND ASSOCIATED ASSEMBLY METHOD
MA50348A (fr) 2017-10-09 2020-08-19 Amgen Inc Dispositif d'administration de médicament comprenant un ensemble d'entraînement et procédé d'assemblage associé
MA50528A (fr) 2017-11-03 2020-09-09 Amgen Inc Systèmes et approches pour stériliser un dispositif d'administration de médicament
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
CA3079197A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
WO2019094138A1 (en) 2017-11-10 2019-05-16 Amgen Inc. Plungers for drug delivery devices
CN111278487B (zh) 2017-11-16 2022-06-24 安进公司 用于药物递送装置的门闩锁机构
MA50903A (fr) 2017-11-16 2021-05-12 Amgen Inc Auto-injecteur avec détection de décrochage et de point d'extrémité
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
WO2020023220A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
US20210228815A1 (en) 2018-07-24 2021-07-29 Amgen Inc. Hybrid drug delivery devices with grip portion
CA3103681A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
CN112351804A (zh) 2018-07-24 2021-02-09 安进公司 用于施用药物的输送装置
CA3103105A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
CA3106452A1 (en) 2018-09-24 2020-04-02 Amgen Inc. Interventional dosing systems and methods
AU2019350660A1 (en) 2018-09-28 2021-03-18 Amgen Inc. Muscle wire escapement activation assembly for a drug delivery device
WO2020072577A1 (en) 2018-10-02 2020-04-09 Amgen Inc. Injection systems for drug delivery with internal force transmission
CA3112214A1 (en) 2018-10-05 2020-04-09 Amgen Inc. Drug delivery device having dose indicator
CN112689523A (zh) 2018-10-15 2021-04-20 安进公司 用于药物递送装置的平台组装方法
EA202191037A1 (ru) 2018-10-15 2021-08-05 Эмджен Инк. Устройство доставки лекарственного средства, имеющее демпферный механизм
US20220031953A1 (en) 2018-11-01 2022-02-03 Amgen Inc. Drug delivery devices with partial needle retraction
MA54057A (fr) 2018-11-01 2022-02-09 Amgen Inc Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
EP3873566A1 (en) 2018-11-01 2021-09-08 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
JP2022529319A (ja) 2019-04-24 2022-06-21 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
AU2020337250A1 (en) 2019-08-23 2022-03-03 Amgen Inc. Drug delivery device with configurable needle shield engagement components and related methods
WO2022086620A1 (en) * 2020-10-20 2022-04-28 The Methodist Hospital System Psma-targeted immunotherapies for cancers
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
JP2003523404A (ja) * 2000-02-25 2003-08-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 乳癌における治療に対する膜エストロゲンレセプター
CA2433800C (en) * 2001-01-05 2016-09-13 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
ES2427964T3 (es) * 2002-01-18 2013-11-05 Pierre Fabre Medicament Nuevos anticuerpos anti-IGF-IR y sus aplicaciones
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US20080193445A1 (en) * 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US20080063639A1 (en) * 2002-01-18 2008-03-13 Pierre Fabre Medicament Method for the treatment of psoriasis comprising novel anti-IGF-IR antibodies
CA2484000A1 (en) * 2002-05-24 2003-12-04 Schering Corporation Neutralizing human anti-igfr antibody
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
GB0219524D0 (en) * 2002-08-21 2002-10-02 Queen Mary & Westfield College Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
ATE549359T1 (de) * 2003-04-02 2012-03-15 Hoffmann La Roche Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen
MXPA06001634A (es) * 2003-08-13 2006-04-28 Pfizer Prod Inc Anticuerpos humanos modificados igf-1r.
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
FR2907341B1 (fr) * 2006-10-18 2012-08-17 Pf Medicament Utilisation d'un anticorps anti-cd151 pour le traitement du cancer

Also Published As

Publication number Publication date
CN101014625A (zh) 2007-08-08
IL181025A0 (en) 2007-07-04
RU2009138977A (ru) 2011-04-27
IL181025A (en) 2013-12-31
CA2575348A1 (en) 2006-02-09
US8420085B2 (en) 2013-04-16
FR2873699B1 (fr) 2009-08-21
IL229778A0 (en) 2014-01-30
SV2006002182A (es) 2006-10-04
NZ552821A (en) 2009-10-30
US20120183559A1 (en) 2012-07-19
ZA200700593B (en) 2008-05-28
RU2007107589A (ru) 2008-09-10
EP2365005A3 (en) 2011-10-26
HK1102600A1 (en) 2007-11-30
KR20070057814A (ko) 2007-06-07
WO2006013472A2 (en) 2006-02-09
EP1771481A2 (en) 2007-04-11
TW200628490A (en) 2006-08-16
EP2365005A2 (en) 2011-09-14
TWI432451B (zh) 2014-04-01
EP2380912A1 (en) 2011-10-26
NO20071093L (no) 2007-02-27
JP5016487B2 (ja) 2012-09-05
WO2006013472A3 (en) 2006-05-11
US8124079B2 (en) 2012-02-28
AU2005268505A1 (en) 2006-02-09
JP2014193862A (ja) 2014-10-09
AR050036A1 (es) 2006-09-20
EP2365006A2 (en) 2011-09-14
NZ569718A (en) 2010-03-26
EP1771481B1 (en) 2014-05-14
KR101220635B1 (ko) 2013-01-11
JP2008515773A (ja) 2008-05-15
US7854930B2 (en) 2010-12-21
JP2012153692A (ja) 2012-08-16
GT200500205A (es) 2006-03-02
FR2873699A1 (fr) 2006-02-03
EP2365006A3 (en) 2011-10-19
CN103951752A (zh) 2014-07-30
RU2406729C2 (ru) 2010-12-20
CN101014625B (zh) 2013-07-03
AU2005268505B2 (en) 2011-11-17
MX2007001109A (es) 2007-04-19
US20090214525A1 (en) 2009-08-27
BRPI0513890A (pt) 2008-05-20
PA8640601A1 (es) 2006-08-03
US20110091479A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
CO5700152A1 (es) Nuevos anticuerpos anti-igf-ir y sus usos
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
ES2547463T3 (es) Moléculas de unión a ILT3 y usos de las mismas
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
GEP20094829B (en) Fully human antibodies against human 4-1bb (cd137)
ES2572231T3 (es) Anticuerpos monoclonales anti-IL-21 humana
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
MY150553A (en) Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
NO20091534L (no) Preparator og fremgangsmater som vedrorer glukagonreseptorantistoff
ES2685823T3 (es) Anticuerpos antagonistas anti-CD40
ECSP078026A (es) Anticuerpos anti-cd40 humanizados y sus métodos de uso
EA200700136A1 (ru) Анти-cd154-антитела
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
CL2012000519A1 (es) Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de carcinoma de células escamosas en un mamífero (div. sol. 3615-07).
CO6190543A2 (es) Anticuerpos anti-factor d humanizados
IL172854A0 (en) Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations
RS52484B (en) CD40 ANTIBODIES
ATE482719T1 (de) Behandlungsverfahren unter verwendung von anti- cd22-antikörpern
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
AR046677A1 (es) Formas solidas de anticuerpos anti-egfr
PE20001316A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que lo contiene
GT200900051A (es) Proteinas de union a interleuquina-13
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
EA200702064A1 (ru) Новое анти-plgf антитело
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf

Legal Events

Date Code Title Description
FA Application withdrawn